Liu Xianfang C, Bell Christopher A, Simmonds Kimberley A, Russell Margaret L, Svenson Lawrence W
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.
Epidemiology and Surveillance Team, Alberta Ministry of Health, 23rd fl Telus Plaza NT, 10025 Jasper Avenue, Edmonton, AB, T5J 1S6, Canada.
BMC Infect Dis. 2016 Jan 13;16:15. doi: 10.1186/s12879-016-1340-6.
In Canada both bivalent (bHPV) vaccine and quadrivalent HPV vaccine (qHPV) are authorized for use. In Alberta, while both vaccines are available for private purchase, only qHPV is publicly funded for school girls in grades 5 and 9 as of 2013. We describe HPV vaccine uptake in Alberta, by school year, from the start of the publicly funded program in the Fall of 2008 through to August 31(st) 2014 and estimate the cumulative proportion of the female population who were vaccinated by the end of the 2013/14 school year.
We used data from the Alberta Ministry of Health Immunization and Adverse Reaction to Immunization repository (publicly funded vaccine), the population-based Pharmaceutical Information Network information systems (privately purchased vaccine) for the period September 1, 2008 to August 31, 2014 and demographic data from the Alberta Health Care Insurance Plan Registry. We estimate vaccine uptake rates and explore them by attributes of person, time, place, vaccine funding, and number of doses received. We estimated the cumulative proportions of the female population (by age group and number of doses received) who had received HPV vaccine by the end of the 2013/14 school year.
Of the 169,259 unique individuals who received one or more doses of HPV vaccine over the period, 98.3% were females, and 83.8% received publicly funded vaccines. Vaccine uptake increased over the period. The cumulative proportion of females aged 9-26 years as of 2013/14 who had received two or more doses of vaccine was 34.3%; for those aged 10-11 years 59.6% and for those aged 14-15 years, 76.0%. For those aged 9-26 years, 31.3% had received three doses of vaccine.
HPV vaccine uptake rates have increased in Alberta over the study period, most prominently among the age groups targeted by the publicly funded school-girl vaccine program.
在加拿大,二价人乳头瘤病毒(bHPV)疫苗和四价人乳头瘤病毒(qHPV)疫苗均被批准使用。在艾伯塔省,尽管两种疫苗都可供私人购买,但截至2013年,只有四价人乳头瘤病毒疫苗在公立学校为五年级和九年级女生提供资金支持。我们描述了从2008年秋季公立资助项目启动到2014年8月31日期间,艾伯塔省各学年的人乳头瘤病毒疫苗接种情况,并估算了截至2013/14学年末接种疫苗的女性人口的累计比例。
我们使用了来自艾伯塔省卫生部免疫和免疫不良反应资料库(公立资助疫苗)、基于人群的药品信息网络信息系统(私人购买疫苗)在2008年9月1日至2014年8月31日期间的数据,以及来自艾伯塔省医疗保险计划登记处的人口统计数据。我们估算疫苗接种率,并按人员、时间、地点、疫苗资金和接种剂量数量等属性进行探究。我们估算了截至2013/14学年末接种过人乳头瘤病毒疫苗的女性人口(按年龄组和接种剂量数量)的累计比例。
在该期间接受一剂或多剂人乳头瘤病毒疫苗的169,259名个体中,98.3%为女性,83.8%接受了公立资助的疫苗。在此期间疫苗接种率有所上升。截至2013/14学年,9至26岁女性中接受两剂或更多剂疫苗的累计比例为34.3%;10至11岁的为59.6%,14至15岁的为76.0%。9至26岁的人群中,31.3%接受了三剂疫苗。
在研究期间,艾伯塔省的人乳头瘤病毒疫苗接种率有所上升,在公立学校女生疫苗项目的目标年龄组中最为显著。